At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 58 enrolled
Drug / intervention
Nivolumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)
In Brief
A Phase 2 clinical trial evaluating Nivolumab for Solid Tumors. Completed, enrolled 58 participants across 2 sites.
Detailed Summary
The purpose of this study is to determine whether nivolumab is safe and effective in the treatment of advanced or recurrent solid tumors in Chinese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumors
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartJan 2016
Primary CompletionSep 2021
TodayJul 2026
First PostedNov 2, 2015
Enrollment StartJan 7, 2016
Primary CompletionSep 27, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 10.7 years ago
Interventions
Nivolumabdrug